Drug delivery company Aviron sold for $1.5 billion
This article was originally published in Clinica
Drug delivery company Aviron is to be bought by biotechnology company MedImmune in an exchange offer and merger transaction valued at around $1.5 billion. Aviron's key product is FluMist, an intranasal flu vaccine that has not yet got FDA clearance.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.